Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression
- 26 May 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (21), 8760-8765
- https://doi.org/10.1073/pnas.0902659106
Abstract
Many ocular pathologies, including retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration, result in vision loss because of aberrant neoangiogenesis. A common feature of these conditions is the presence of hypoxic areas and overexpression of the proangiogenic vascular endothelial growth factor (VEGF). The prevailing current treatment, laser ablation of the retina, is destructive and only partially effective. Preventive and less destructive therapies are much more desirable. Here, we show that mice lacking c-Jun N-terminal kinase 1 (JNK1) exhibit reduced pathological angiogenesis and lower levels of retinal VEGF production in a murine model of ROP. We found that hypoxia induces JNK activation and regulates VEGF expression by enhancing the binding of phospho-c-Jun to the VEGF promoter. Intravitreal injection of a specific JNK inhibitor decreases retinal VEGF expression and reduces pathological retinal neovascularization without obvious side effects. These results strongly suggest that JNK1 plays a key role in retinal neoangiogenesis and that it represents a new pharmacological target for treatment of diseases where excessive neoangiogenesis is the underlying pathology.Keywords
This publication has 48 references indexed in Scilit:
- Angiogenesis as a therapeutic targetNature, 2005
- Inhibition of c‐Jun N‐terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized ratsBritish Journal of Pharmacology, 2004
- A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemiaNature Medicine, 2003
- AP-1 as a regulator of cell life and deathNature Cell Biology, 2002
- Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degenerationNature Genetics, 2001
- c-JUN Gene Induction and AP-1 Activity Is Regulated by a JNK-Dependent Pathway in Hypoxic HepG2 CellsExperimental Cell Research, 2001
- Inhibition of C-Jun N-Terminal Kinase 1, but Not c-Jun N-Terminal Kinase 2, Suppresses Apoptosis Induced by Ischemia/Reoxygenation in Rat Cardiac MyocytesMolecular Pharmacology, 2001
- Stress-activated Protein Kinases (JNK and p38/HOG) Are Essential for Vascular Endothelial Growth Factor mRNA StabilityJournal of Biological Chemistry, 2000
- Vitreal macrophages express vascular endothelial growth factor in oxygen‐induced retinopathyClinical & Experimental Ophthalmology, 2000
- Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathwayMolecular and Cellular Biochemistry, 1999